InMed Pharmaceuticals Inc. (INM) · Nov 5, 2026 · Acquisition
Merger approved — Key merger proposals approved; 1-for-10 consolidation completed
InMed’s merger vote cleared the Mentari transaction and completed a 1-for-10 consolidation, but closing conditions remain outstanding.
InMed is in the middle of a reverse-merger pivot into Mentari’s migraine-prevention pipeline, while preparing to separate or preserve value for its legacy assets. The merger was announced on May 19, 2026, and the shareholder vote, registration statement, consolidation and CVR mechanics were already scheduled or disclosed before this filing.
The vote removes a meaningful transaction hurdle, but it does not complete the transaction. Shareholders approved the Nasdaq share issuance, return-of-capital and redomestication proposals needed for the deal, and the company said an adjournment was unnecessary because enough votes supported the Nasdaq share issuance. 〔0〕 The remaining uncertainty is procedural rather than resolved: the filing explicitly says closing is still subject to the satisfaction or waiver of the merger agreement’s other conditions. 〔1〕
The 1-for-10 consolidation changes the share count and trading mechanics, not the underlying business. Outstanding shares fell from 5,493,735 to approximately 549,374, with proportional adjustments to options, warrants and the equity plan. 〔2〕 Nasdaq trading on a post-consolidation basis is expected to begin November 5, 2026, but this is largely execution of the previously announced transaction structure rather than new operating progress.
The CVR record-date detail creates a near-term ownership cutoff for existing holders. Shareholders of record at the close of business on November 5 are expected to receive one CVR per post-consolidation share, while investors purchasing on November 5 are not expected to qualify. 〔3〕 The filing does not quantify the potential CVR payments, so their economic value remains unclear.
Bottom line: This is a modest step forward for the Mentari transaction because shareholder approval is now in hand, but the core business transition remains uncompleted. The consolidation is mostly mechanical, so the filing advances the existing story without rewriting it.
Merger closing after remaining conditions are satisfied
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!